Corwin Dale Hooks
Corporate Officer/Principal bei APPLIED THERAPEUTICS, INC.
Vermögen: 1 Mio $ am 31.05.2024
Aktive Positionen von Corwin Dale Hooks
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
APPLIED THERAPEUTICS, INC. | Corporate Officer/Principal | 12.04.2024 | - |
Karriereverlauf von Corwin Dale Hooks
Ehemalige bekannte Positionen von Corwin Dale Hooks
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2019 | 01.01.2023 |
CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | 01.08.2014 | 29.10.2018 |
Vertrieb & Marketing | 01.08.2014 | - | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Vertrieb & Marketing | 01.01.2004 | 01.01.2014 |
Ausbildung von Corwin Dale Hooks
The University of North Carolina at Charlotte | Masters Business Admin |
Stephen F. Austin State University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
2 |
Operativ
Corporate Officer/Principal | 3 |
Sales & Marketing | 2 |
Masters Business Admin | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Applied Therapeutics, Inc. | |
Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
- Börse
- Insiders
- Corwin Dale Hooks
- Erfahrung